
Double fat jab health warning as women told risks to unborn babies are unknown & injections may affect the pill
WOMEN on fat jabs must take effective contraception, health chiefs have warned for the first time.
It comes amid claims of an ' Ozempic baby boom ' - with more women becoming pregnant while using weight-loss injections like Wegovy and Mounjaro.
3
To date, the Medicines and Healthcare products Agency (MHRA) has received more than 40 pregnancy-related reports involving the jabs, with women online raising fears after discovering they're pregnant while taking the drugs.
Now, top doctors say the drugs must not be used during pregnancy, while trying to conceive or breastfeeding, over fears they could lead to miscarriage or birth defects.
The MHRA said today: 'This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby.'
Dr Bassel Wattar, a consultant gynaecologist and medical director of clinical trials at Anglia Ruskin University, told The Sun: 'It's not the medication itself, but the weight loss that helps regulate a woman's hormones allowing her ovaries to function properly again.
'Pregnancy is more of a happy side effect.'
What's more, it is thought that GLP-1 drugs could reduce the absorption of contraceptives, due to the fact they slow down the emptying of the stomach.
Professor Rebecca Reynolds from the University of Edinburgh warned we don't fully understand the effects these drugs could have on an unborn baby, due to a lack of scientific evidence.
She said: 'There is hardly any available data from human studies to be able to advise if these weight loss drugs are safe in pregnancy.
'The data from animal studies suggest the potential for harm with low birth weight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in pregnant humans.'
Dr Wattar added it is rare for pregnant women to be involved in trials like this, due to the fact it can be 'riskier and more expensive'.
Julia Hartley-Brewer slams government plan for NHS to offer free 'fat jabs' to tackle obesity crisis
Studies on pregnant rats showed semaglutide - the active drug in Wegovy and Ozempic - caused early pregnancy loss and birth defects.
Meanwhile, similar results were seen in rabbits and monkeys, with miscarriages and developmental issues found in offspring.
The MHRA says women should use reliable contraception if they are taking GLP-1 weight-loss injections, and for up to two months between stopping the jabs and trying to get pregnant.
3
That means women should take either the oral pill or non-oral options, the implant, coil or use condoms effectively.
The MHRA guidance also warns those specifically taking Mounjaro to use a non-oral method of contraception after studies found the active drug tirzepatide may reduce the effectiveness of oral contraceptives in women who are overweight.
Dr Alison Cave, from the Medicines and Healthcare products Regulatory Agency (MHRA), said: "This guidance should not be used as a substitute for reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process."
'The power to harm as well as to heal'
The warning comes as the jabs fuel a boom in demand, with community pharmacies seeing a surge in requests.
Jasmine Shah, of the National Pharmacy Association (NPA), said: "Medicines are not like ordinary goods for sale, they must be handled with great care because they have the power to harm as well as to heal."
Officials also warned against buying the jabs from dodgy sellers online or in beauty salons, where fake or unsafe products could pose a serious risk.
DR Zoe Williams is The Sun's resident GP.
Q: What if I am pregnant and taking fat jabs?
The fact these drugs suppress appetite means the majority of women who got pregnant on them will have come off, because they are nourishing their baby.
The advice is to come off them immediately if you're either pregnant or breastfeeding and speak to your doctor if you have any concerns.
Q: Why has this advice been issued now?
It is because not enough is known about the effect on pregnancy.
It's not from studies that found any adverse effects.
As a result, the advice is preventative until more is known.
If women are on any weight loss jabs and want a baby, the advice is to come off it at least two months before trying.
Q: Are fat jabs going to be the 'new thalidomide' scandal?
No, the GLP-1 drugs are peptides that work by mimicking existing proteins in our bodies. In contrast, thalidomide is a drug that can affect blood vessel growth.
It is not likely that the jabs would cause such significant birth defects, as seen with thalidomide.
So far there has been no evidence of danger to the baby, despite many women getting pregnant on them.
Q: I'm worried and don't know what to do?
When news like this breaks, it is common to have patients get in touch with concerns.
Stop taking the medication.
But be reassured, there is nothing your GP or midwife will need to do urgently.
If they are really concerned, they will get in touch.
Anyone concerned about side effects, including severe stomach pain that radiates to the back, a sign of pancreatitis, should seek medical help immediately.
GLP-1 drugs work by mimicking hormones that make you feel full, and some, like Mounjaro, also target blood sugar control.
A spokesperson for Novo Nordisk that makes Wegovy and Ozempic, told The Sun: 'There is limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse maternal and foetal outcomes.
'Semaglutide should be discontinued in women at least two months before a planned pregnancy due to the long washout period.
'Semaglutide should not be used in pregnancy. Women of childbearing potential are recommended to use contraception when treated with semaglutide.
'In other pharmacology trials, semaglutide did not affect the absorption of oral medications (including the oral contraceptive medication ethinylestradiol and levonorgestrel) to any clinically relevant degree.
'Therefore semaglutide is not anticipated to decrease the effect of oral contraceptives.
'Nonetheless, caution should be exercised when oral medications are concomitantly administered with semaglutide.'
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
40 minutes ago
- The Independent
Reeves announces £6 billion to provide millions of NHS tests and procedures
Rachel Reeves has announced a £6 billion investment to speed up tests and treatment within the NHS, after setting out huge year-on-year rises in the health service's budget. New scanners, ambulances and urgent treatment centres are among the things which the additional cash will pay for, with the aim of providing up to four million more tests and procedures over the next five years. The announcement comes after the Chancellor put NHS funding at the heart of her spending review on Wednesday, raising its budget in a move worth £29 billion a year. This comes, however, at the expense of other areas of public spending. The new £6 billion funding will help to meet the Government's target of reducing NHS waiting lists in England, the Chancellor claimed. 'Over a decade of underinvestment from the previous government put the NHS on its knees, with people across the country unable to get the care they need. We are investing in Britain's renewal, and we will turn that around,' Ms Reeves said. She added: 'Part of our record investment will deliver four million tests, scans and procedures, so hard-working people can get the healthcare they and their families need. 'There is no strong economy without a strong NHS, and we'll deliver on our Plan for Change to end the hospital backlog, improve living standards and get more money in people's pockets.' The latest spending commitment will help patients get access to diagnostic scans and treatment in places such as shopping centres and high streets, speeding up their diagnoses. The Government hopes this will help to cut NHS waiting lists, meeting Labour's goal of ensuring the health service carries out 92% of routine operations within 18 weeks. Health Secretary Wes Streeting said: 'Since taking office we have been relentless in our drive to cut waiting times for patients, delivering over 3.6 million extra elective care appointments and reducing the overall waiting list by over 200,000. 'The £6 billion investment we are announcing today will generate millions more vital diagnostic tests, scans and procedures for patients across the country.' On Wednesday evening, Ms Reeves said the Government was 'confident' it could meet its pledge to reduce waiting lists after giving the NHS a 3% annual increase in funding at the spending review. Some health leaders are, however, sceptical that the Government will meet its target, despite the funding boost provided at the spending review. Matthew Taylor, chief executive of the NHS Confederation, which represents all health organisations, warned 'difficult decisions will still need to be made as this additional £29 billion won't be enough to cover the increasing cost of new treatments, with staff pay likely to account for a large proportion of it'. He added: 'So, on its own, this won't guarantee that waiting time targets are met.' Sarah Woolnough, chief executive of the King's Fund charity, said: 'The Chancellor said she wants the public to have an NHS there when they need it. 'It is hard to see how all the things she mentions: faster ambulance times, more GP appointments, and adequate mental health services and more can be met on this settlement alone. 'Particularly when large parts of this additional funding will be absorbed by existing rising costs, such as the higher cost of medicines, which are currently being negotiated, and covering staff pay deals.'


The Independent
an hour ago
- The Independent
NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms
Rachel Reeves has pledged a £6bn investment aimed at accelerating tests and treatments within the NHS, following substantial year-on-year budget increases for the health service. The additional funding will facilitate new scanners, ambulances, and urgent treatment centres, with the goal of delivering up to four million more tests and procedures over the next five years. This announcement follows the chancellor's emphasis on NHS funding in her recent spending review, where she allocated an additional £29bn annually to the NHS budget. However, this increase comes at the expense of other areas of public spending. The £6bn boost is intended to support the Government's objective of reducing NHS waiting lists in England, according to the chancellor. 'Over a decade of underinvestment from the previous government put the NHS on its knees, with people across the country unable to get the care they need. We are investing in Britain's renewal, and we will turn that around,' Ms Reeves said. She added: 'Part of our record investment will deliver four million tests, scans and procedures, so hard-working people can get the healthcare they and their families need. 'There is no strong economy without a strong NHS, and we'll deliver on our Plan for Change to end the hospital backlog, improve living standards and get more money in people's pockets.' The latest spending commitment will help patients get access to diagnostic scans and treatment in places such as shopping centres and high streets, speeding up their diagnoses. The Government hopes this will help to cut NHS waiting lists, meeting Labour's goal of ensuring the health service carries out 92 per cent of routine operations within 18 weeks. Health Secretary Wes Streeting said: 'Since taking office we have been relentless in our drive to cut waiting times for patients, delivering over 3.6 million extra elective care appointments and reducing the overall waiting list by over 200,000. 'The £6bn investment we are announcing today will generate millions more vital diagnostic tests, scans and procedures for patients across the country.' On Wednesday evening, Ms Reeves said the Government was 'confident' it could meet its pledge to reduce waiting lists after giving the NHS a 3 per cent annual increase in funding at the spending review. Some health leaders are, however, sceptical that the Government will meet its target, despite the funding boost provided at the spending review. Matthew Taylor, chief executive of the NHS Confederation, which represents all health organisations, warned 'difficult decisions will still need to be made as this additional £29bn won't be enough to cover the increasing cost of new treatments, with staff pay likely to account for a large proportion of it'. He added: 'So, on its own, this won't guarantee that waiting time targets are met.' Sarah Woolnough, chief executive of the King's Fund charity, said: 'The chancellor said she wants the public to have an NHS there when they need it. 'It is hard to see how all the things she mentions: faster ambulance times, more GP appointments, and adequate mental health services and more can be met on this settlement alone. 'Particularly when large parts of this additional funding will be absorbed by existing rising costs, such as the higher cost of medicines, which are currently being negotiated, and covering staff pay deals.'


Daily Mail
2 hours ago
- Daily Mail
UK Pharmaceutical industry at risk from government's 'sky-high' rebates system
The UK's status as a leader in medical research is at risk from 'sky-high and unpredictable' repayments pharmaceutical firms hand the Government, says an industry boss. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said the rebate system – where firms repay money they make through selling medicines to the NHS – was sending 'a terrible message to international investors'. Rachel Reeves promised to support 'the UK's strengths in life sciences' and 'ensure patients get rapid access to the most clinically and cost-effective new technologies'. The Treasury plans to invest up to £520million in drug manufacturing in the next five years. Another £600million is earmarked for a health data research service to accelerate the discovery of new medicines. But Torbett said more was needed. 'Over the past decade, accounting for inflation, the NHS budget has grown by a third in real terms, while investment in the most rigorously cost-benefit-tested part of health spending – investment in the medicines needed to treat people – has fallen from around 11 per cent to 9 per cent of the health budget,' he added. And he attacked plans to increase what drug companies must repay from drug sales to 31.3 per cent, from 15.5 per cent. 'The sky-high and unpredictable payment rates send a terrible message to international investors when the UK is trying to position life sciences research and development as an engine for health and growth. For the sake of patients, the NHS and the economy, we need a commitment to bring these unsustainable rates down.'